Arthi Vijayaraghavan

Summary

Publications

  1. ncbi Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany
    Arthi Vijayaraghavan
    McKesson Corporation, San Francisco, CA 94587, USA
    Int J Cancer 131:438-45. 2012
  2. ncbi Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world
    Arthi Vijayaraghavan
    Mosaic Health Care Consultants, Larkspur, CA, USA
    J Acquir Immune Defic Syndr 46:91-100. 2007
  3. ncbi Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa
    Arthi Vijayaraghavan
    McKesson Corporation, 15 Hillcrest Avenue, Larkspur, CA 94939, USA
    Gynecol Oncol 112:377-83. 2009
  4. ncbi Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening
    Arthi Vijayaraghavan
    McKesson Corp, San Francisco, California, USA
    Gynecol Oncol 119:237-42. 2010
  5. ncbi Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Québec, Canada
    Arthi Vijayaraghavan
    McKesson Corp, San Francisco, CA, USA
    Can J Public Health 101:220-5. 2010

Detail Information

Publications5

  1. ncbi Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany
    Arthi Vijayaraghavan
    McKesson Corporation, San Francisco, CA 94587, USA
    Int J Cancer 131:438-45. 2012
    ..Under most scenarios, using KRAS testing to select patients for EGFR inhibitor therapy saved $7,500-$12,400 per patient in the United States and €3,900-€9,600 per patient in Germany with equivalent clinical outcomes...
  2. ncbi Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world
    Arthi Vijayaraghavan
    Mosaic Health Care Consultants, Larkspur, CA, USA
    J Acquir Immune Defic Syndr 46:91-100. 2007
    ..Determine the cost-effectiveness of initiating and monitoring highly active antiretroviral therapy (HAART) in developing countries according to developing world versus developed world guidelines...
  3. ncbi Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa
    Arthi Vijayaraghavan
    McKesson Corporation, 15 Hillcrest Avenue, Larkspur, CA 94939, USA
    Gynecol Oncol 112:377-83. 2009
    ..To determine the cost effectiveness of several cervical cancer screening strategies utilizing HPV testing in South Africa...
  4. ncbi Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening
    Arthi Vijayaraghavan
    McKesson Corp, San Francisco, California, USA
    Gynecol Oncol 119:237-42. 2010
    ..Our objective was to determine the cost-effectiveness of adding HPV-16 and 18 genotype triage to current cervical cancer screening strategies in the United States...
  5. ncbi Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Québec, Canada
    Arthi Vijayaraghavan
    McKesson Corp, San Francisco, CA, USA
    Can J Public Health 101:220-5. 2010
    ..Our objective was to evaluate the cost-effectiveness of cervical cancer screening strategies utilizing HPV testing...